Aller au contenu principal
Accès ouvert déclaré 2025 article

Inhibition of endocannabinoid synthesis enzymes DAGL and NAPE-PLD transiently lowers body weight and alters glucose homeostasis during a high-fat diet challenge in mice

1Citations signalées, ce qui n’est pas une note de qualité
4Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : nl. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND: Cannabinoid receptor 1 inhibition poses an effective treatment strategy in obesity, but has a risk of psychiatric side effects. As high-fat diet (HFD)-feeding acutely increases expression of endocannabinoid synthesis enzymes and circulating endocannabinoid levels in mice, here we tested whether inhibition of these enzymes alleviates metabolic disturbances caused by high-fat diet feeding. METHODS: C57BL/6J mice received daily intraperitoneal injections with a NAPE-PLD inhibitor (LEI-401), DAGL inhibitor (DH-376), or vehicle for 1 week while on a HFD. An extra group of vehicle-treated mice was maintained on regular chow diet. RESULTS: Both inhibitors effectively lowered blood and brain levels of endocannabinoids after 1 week of treatment. DH-376 reduced plasma insulin levels compared with vehicle (-53%) already within 2 h after the first dose. In contrast, LEI-401 did not change insulin or glucose levels. Both inhibitors suppressed caloric intake during the first day of treatment (-25% and -21%, respectively). In addition, LEI-401 elevated carbohydrate oxidation. The combined effect was a 2.0 and 1.6 g lower body weight after 24 h, respectively. Nevertheless, after 1 week body weight was no longer different between the HFD-fed groups. Moreover, DH-376 increased brown adipose tissue weight and reduced insulin-stimulated glucose uptake. CONCLUSIONS: DAGL and NAPE-PLD inhibition effectively lower levels of endocannabinoids and related bioactive lipids. Both inhibitors caused a transient reduction in food intake and body weight, but also led to alterations in glucose homeostasis. The long-term effects of endocannabinoid biosynthesis inhibitors on (cardio)metabolic health remains to be investigated.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Inhibition of endocannabinoid synthesis enzymes DAGL and NAPE-PLD transiently lowers body weight and alters glucose homeostasis during a high-fat diet challenge in mice
Date Crossref
15/10/2025
Éditeur
Oxford University Press (OUP)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Cannabis and Cannabinoid ResearchNeuroscience of respiration and sleepAdipose Tissue and Metabolism

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.